Terri Robertson's diverse career has centered around creating connections through communication. And after 9 years at Medtronic, she has moved into a role that finds ways to build connections directly with patients. By developing tools that empower Medtronic teams to actively seek and incorporate patient feedback into processes, procedures, and products, Terri’s work ultimately drives innovation and enhances patient experiences and outcomes.

Sam has 20 years of experience in industry managing medical affairs and commercial service provider companies and specializes in partnerships with biotechnology firms. He has partnered with dozens of biotechnology leadership teams across asset and company lifecycle stages to support corporate strategy, asset development, pre-launch, launch, and LCM activities. He earned his PhD from the University of South Florida, College of Medicine and conducted his academic research at the H. Lee Moffitt Cancer Center and Research Institute Drug Discovery Program. He has held pro bono positions including with the NCI-CCOP program and is an invited speaker on rare diseases. He is currently on the Inizio Medical executive leadership team where he leads biotechnology customer segment and is the global president for the premier medical affairs service provider ApotheCom as well as the MEDiSTRAVA biotechnology integrated services team.

Kelly Covello, PhD, is an oncology leader with more than 20 years of experience across research, clinical development, and medical affairs. She joined RayzeBio in 2025 as Head of Medical.

Before RayzeBio, Kelly served as Head of Medical at Mirati Therapeutics, where she spent almost five years building and leading a global medical organization, supporting the commercialization of KRAZATI, and driving scientific communications, external engagement and data-generation to support research and development of pipeline assets. Prior to Mirati, Kelly spent over a decade at Bristol Myers Squibb in diverse leadership roles, including Senior Early Development Team Lead for Immuno-Oncology where she guided strategy and entry of a portfolio for early pipeline assets into the clinic through clinical proof and concept and was the Global Medical Lead for Lung Cancer for Opdivo and Yervoy.

Her earlier career included various roles at GlaxoSmithKline, Boehringer Ingelheim, and other positions at Bristol Myers Squibb, expanding her depth in translational medicine, biomarkers, and precision oncology. Kelly is passionate about building empowered, diverse teams and fostering a culture of innovation to deliver meaningful advances for cancer patients.

Kelly earned her PhD in Cell and Molecular Biology from the University of Pennsylvania School of Medicine and her BS in Biology from The College of New Jersey.

Guowei Fang, PhD joined Legend Biotech in March 2022 and serves as the President of Research and Development. Dr. Fang has held positions at Legend with increasing responsibilities, including Senior Vice President, Global Head of Research and Early Development, Chief Scientific Officer, and Head of Business Development. As an accomplished scientist and pharmaceutical leader, Dr. Fang brings a wealth of experience in oncology and immunology to the role.

Prior to Legend, Dr. Fang was the Senior Vice President of Research at Zymeworks Inc., overseeing the development of novel platforms and a portfolio of multi-functional biologics and antibody-drug conjugates. Before that, Dr. Fang led discovery and early development initiatives as Head of Discovery at Pharmacyclics, an AbbVie company. In that role, he built the Research, Discovery, Translation, and Clinical Pharmacology organizations, delivered a broad pipeline of hematological assets, and supported the clinical development of IMBRUVICA®. Dr. Fang also held positions at AbbVie and Genentech with a focus on oncology research and discovery. Prior to transitioning into the pharmaceutical industry, he was a faculty member at Stanford University, leading cancer research initiatives.

Dr. Fang earned his Ph.D. from the University of Colorado and completed his postdoctoral training at Harvard Medical School. He also holds a BS in biochemistry from Nanjing University. Dr. Fang has published over 60 manuscripts in cancer research and drug discovery and development, including primary publications in Science, Nature, and Cell.

Igor Bilinsky, PhD joined Iovance in March 2021. He has more than 20 years of cumulative leadership experience through prior roles as Chief Executive Officer, Chief Operating Officer and Chief Business Officer at companies within the life sciences industry. Prior to joining Iovance he served as Chief Business Officer of Oncternal Therapeutics, where he was integral in building the publicly traded oncology company. Previously, Dr. Bilinsky served as Chief Operating Officer of AmpliPhi Biosciences, and as General Manager of Immuno-oncology and Senior Vice President at IGNYTA (now part of Roche). His prior experience also includes senior executive roles at Vical and Halozyme Therapeutics, and Chief Executive Officer at Androclus Therapeutics. He also served as a principal in the healthcare practice of Boston Consulting Group. Dr. Bilinsky received a B.S. in Physics from the Moscow Institute of Physics and Technology and a Ph.D. in Physics from the Massachusetts Institute of Technology.

Over the past 25 years, Billy has developed statistical methodologies to inform and support strategic decision making in healthcare. Prior to joining Phastar, Billy led the model-based drug development team at Novartis. Then, he developed and led implementation of statistical methodologies for high impact research sponsored by public and global Health Agencies (EFSA, Global Fund, US NIH). Billy has been Senior VP at Certara in charge of data and decision analytics and CEO/Chief statistician at Quinten Health an AI company pioneering digital twins and disease modeling.

Billy still acts as statistical expert for public health organizations such as EMA, WHO and Gates Foundation.

He led hundreds of trial design and analytics projects, authored more than 100 publications, defended/submitted 100 regulatory and reimbursements dossiers, and led hundreds of data modelling or machine learning projects.

Gerben Moolhuizen joined Abalos in October 2024. He brings to Abalos over 25 years of experience in the biopharma industry in a variety of roles, including business development, project management, and general management covering a broad range of indications and therapeutic modalities. Gerben obtained a M.Sc. in molecular biology from Utrecht University and an M.B.A. from Erasmus University Rotterdam, both in The Netherlands.

Mike Comeau has over 30 years of experience in the biotech industry, with a career dedicated to researching novel immunological pathways and leading the development of numerous therapeutic programs. His work has spanned various indications, including autoimmune, inflammatory disease, and oncology. Mike joined Ozette in 2023 and currently leads the company's strategic scientific alliances efforts.

As Director of Biopharma Partnerships, Jeff facilitates client relationships with RareCyte’s Precision Biology Services group. He has over 10 years of experience in business development and sales for life science technologies and tools, which was preceded by 10 years of biomedical research and development as a student and in post graduate scientific roles. His technical experience has included biosensors, immunoassays, gene editing, liquid biopsy testing, and spatial biology. Jeff obtained his PhD in Bioengineering from the University of Washington and his BE in Biomedical Engineering from Vanderbilt University.

Min. Robert (Bobby) Wiseman, Jr. is a scholar-practitioner, ordained minister, and community advocate whose vocation lives at the intersection of faith, public health, education, and social justice. Rooted in the African philosophy of Ubuntu—“I am because we are”—and his guiding praxis, The Word and The Work: Liberative Whole Heart Hospitality, Wiseman approaches leadership as a communal, adaptive, and liberative practice that prioritizes dignity, belonging, and collective healing.

With over twenty years of ministry and leadership experience across Black Church traditions, including Church of God in Christ (COGIC), Baptist, and United Church of Christ contexts, Wiseman brings a Spirit-led, relational approach to pastoral care and institutional leadership. His ministry is shaped by both proclamation and practice—honoring the sacred while confronting silence, stigma, and systemic inequities related to mental health, sexuality, disability, and healthcare access.

Wiseman’s work extends beyond the sanctuary into national public health and policy spaces. He has served as an invited speaker and advisor for the U.S. Food and Drug Administration, the Duke-Margolis Institute for Health Policy, and the National AIDS Memorial Grove. He currently serves on the Experts by Experience Advisory Committee at the Patient Insight Institute and the Uniqure/CSL Behring Novel Therapies Advisory Committee, centering lived experience and ethical rigor in patient-centered research and innovation.

As a mentor and instructor with the SolanoConnex Community Fellowship and a contributing member of the PATIENTS Professors Academy, Wiseman equips faith leaders, frontline workers, and researchers to engage communities with cultural humility, trust, and accountability. Across pulpits, classrooms, clinics, and community spaces, his calling remains constant: to build tables wide enough for every story, to bridge sacred and secular institutions, and to witness to a Pentecostal imagination where healing, justice, and hospitality move together for the good of all God’s people.

Jennie H. Flanagan, RN, CCRP, MHA is a seasoned healthcare professional with more than 30 years of experience across clinical care, clinical research, education, and healthcare administration. A registered nurse and Certified Clinical Research Professional with a Master’s in Healthcare Administration, she has built her career around improving patient outcomes, safety, and system efficiency. Jennie’s work is deeply informed by her lived experience as a long-time patient managing chronic disease and as a two-time breast cancer survivor, shaping her commitment to patient advocacy, mentorship, and compassionate, high-quality care.

Since July 2024, Jennie has served as Chief Operating Officer of the Community Health Center of Northern New York, a federally qualified health center with four clinical sites and comprehensive services including dental, behavioral health, optometry, and Women, Infants & Children (WIC). In this role, she oversees more than 100 employees and 17 practice managers while leading operational strategy, quality improvement, and access to care initiatives. Previously, she spent three years as a Clinical Research Nurse Coordinator in the St. Lawrence Health Clinical Research Department, contributing to the advancement of patient-centered research and safety.

In addition to her executive leadership, Jennie is a senior lecturer in SUNY Canton’s Bachelor’s program in Healthcare Management, allowing her to remain clinically grounded while helping prepare the next generation of healthcare leaders. She serves as an advisory member with the University of Maryland through the PCORI network and is an active member of the Society of Clinical Research Associates. Across all roles, Jennie remains dedicated to advancing equitable, patient-centered healthcare and mentoring individuals—particularly those facing cancer—through advocacy, education, and leadership.

Misha Mehta is a scientist by training, a Board-Certified Patient Advocate, and above all a mother to her beloved son, Neev, whose brain tumor journey continues to inspire her work. That lived experience fuels her commitment to transforming pediatric brain cancer research, advocacy, and care.

She currently serves as Senior Director of Research at the Pediatric Brain Tumor Foundation, where she leads research strategy and cross-sector collaborations aimed at accelerating discovery and improving access to clinical trials. Misha is also the Founder and President of the Neev Kolte & Brave Ronil Foundation, working alongside families, researchers, clinicians, and policymakers to advance rare cancer research, dismantle data silos, and strengthen support systems for children and families facing devastating diagnosis.

Her advocacy spans national and federal efforts, including contributions to the White House Cancer Moonshot, rare disease policy work as a Legislative Advisor with the EveryLife Foundation, and service on advisory and scientific review boards with the Coalition Against Childhood Cancer, Friends of Cancer Research, PCORI, and the Department of Defense’s Congressionally Directed Medical Research Programs. At the heart of all her work is her son Neev whose courage continues to shape her mission and drive lasting change for children with brain tumors.